Payment overview · 2025
General Payments
$1,416.22
37 reported records · 15 companies
Healthcare provider profile · identity verified
Ashok N Melvani, MD
Allopathic & Osteopathic Physicians|Family Medicine · VICTORVILLE, CA · NPI 1447334099
Verified facts
What the public records show
CMS Open Payments records show Ashok N Melvani, MD received $1,416.22 in general payments during 2025 across 37 reported records.
AstraZeneca Pharmaceuticals LP accounted for 16.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 123 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $233.80 | 16.5% | 6 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $150.00 | 10.6% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $136.89 | 9.7% | 11 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $125.00 | 8.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $125.00 | 8.8% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $125.00 | 8.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $116.07 | 8.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $112.31 | 7.9% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $85.79 | 6.1% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $61.67 | 4.3% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.09 | 2.5% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.41 | 2.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.10 | 2.1% | 1 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.50 | 1.8% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $19.59 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,416.22 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $216.70 | 5 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $136.89 | 11 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $116.07 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $112.31 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $85.79 | 3 | 2025 |
Source payment records
|
|||||
| TALTZ Normalized: taltz |
Drug | Lilly USA, LLC | $38.04 | 2 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $30.10 | 1 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $25.50 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $23.63 | 1 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $18.64 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.45 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
143 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
123 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 492 | 155 |
| Metformin Hcl | Metformin Hcl | 342 | 110 |
| Amlodipine Besylate | Amlodipine Besylate | 329 | 100 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 322 | 80 |
| Lisinopril | Lisinopril | 306 | 84 |
| Gabapentin | Gabapentin | 290 | 87 |
| Losartan Potassium | Losartan Potassium | 262 | 78 |
| Omeprazole | Omeprazole | 258 | 67 |
| Levothyroxine Sodium | Levothyroxine Sodium | 254 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 251 | 77 |
| Simvastatin | Simvastatin | 248 | 72 |
| Tramadol Hcl | Tramadol Hcl | 219 | 74 |
| Azithromycin | Azithromycin | 196 | 115 |
| Metoprolol Succinate | Metoprolol Succinate | 193 | 60 |
| Furosemide | Furosemide | 186 | 53 |
| Ibuprofen | Ibuprofen | 179 | 61 |
| Meloxicam | Meloxicam | 168 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 166 | 53 |
| Ozempic | Semaglutide | 143 | 26 |
| Eliquis | Apixaban | 123 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 122 | 38 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 36 |
| Carvedilol | Carvedilol | 102 | 25 |
| Alendronate Sodium | Alendronate Sodium | 91 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 91 | 23 |
| Tizanidine Hcl | Tizanidine Hcl | 89 | 33 |
| Atenolol | Atenolol | 87 | 23 |
| Citalopram Hbr | Citalopram Hydrobromide | 87 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 86 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 80 | 35 |
| Alprazolam | Alprazolam | 77 | 27 |
| Baclofen | Baclofen | 77 | 12 |
| Metformin Hcl Er | Metformin Hcl | 76 | 20 |
| Finasteride | Finasteride | 75 | 25 |
| Buspirone Hcl | Buspirone Hcl | 73 | 24 |
| Glipizide | Glipizide | 73 | 24 |
| Clonidine Hcl | Clonidine Hcl | 72 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 70 | 23 |
| Cephalexin | Cephalexin | 68 | 57 |
| Lorazepam | Lorazepam | 67 | 15 |
| Allopurinol | Allopurinol | 65 | 20 |
| Trazodone Hcl | Trazodone Hcl | 64 | 18 |
| Enalapril Maleate | Enalapril Maleate | 62 | 16 |
| Potassium Chloride | Potassium Chloride | 62 | 19 |
| Famotidine | Famotidine | 61 | 17 |
| Glimepiride | Glimepiride | 61 | 21 |
| Montelukast Sodium | Montelukast Sodium | 58 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 13 |
| Prednisone | Prednisone | 57 | 45 |
| Sertraline Hcl | Sertraline Hcl | 57 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 55 | 38 |
| Pioglitazone Hcl | Pioglitazone Hcl | 51 | 11 |
| Temazepam | Temazepam | 51 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 50 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 48 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 47 | 13 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 46 | 14 |
| Benazepril Hcl | Benazepril Hcl | 45 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 36 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 41 | 14 |
| Sildenafil Citrate | Sildenafil Citrate | 41 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 38 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 38 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Mupirocin | Mupirocin | 37 | 17 |
| Sucralfate | Sucralfate | 37 | suppressed |
| Xarelto | Rivaroxaban | 37 | suppressed |
| Lovastatin | Lovastatin | 34 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 33 | 11 |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 30 | 22 |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 29 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 29 | suppressed |
| Januvia | Sitagliptin Phosphate | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | suppressed |
| Qvar Redihaler | Beclomethasone Dipropionate | 28 | suppressed |
| Jardiance | Empagliflozin | 27 | suppressed |
| Nifedipine Er | Nifedipine | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 24 | suppressed |
| Glipizide Er | Glipizide | 24 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Ondansetron Odt | Ondansetron | 22 | 14 |
| Enulose | Lactulose | 21 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 17 |
| Colchicine | Colchicine | 19 | 13 |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Lactulose | Lactulose | 17 | 11 |
| Naproxen | Naproxen | 17 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 16 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 13 |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Latanoprost | Latanoprost | 15 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Ciclopirox | Ciclopirox | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Ofloxacin | Ofloxacin | 11 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Spironolactone | Spironolactone | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,416.22 · 37 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, BREZTRI, Bimzelx, CAPLYTA, COMIRNATY, DUPIXENT, FREESTYLE LIBRE 3, MOUNJARO, PREVNAR 20, PURIFIED CORTROPHIN GEL, REZDIFFRA, TALTZ, TAVNEOS, VOQUEZNA, VYNDAQEL, WINREVAIR, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error